NCT03190915
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 221 versions: 14 with changes below, 36 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Collaborators expanded, about 3 words
- Minor Collaborators shortened, about 3 words
Notable Eligibility criteria shortened, about 1 word Show 5 more changesShow less
- Study completion pushed from Oct 3, 2026 to Oct 14, 2027
- Secondary endpoints: details revised at 5 of 6 entries
- Site details revised at 40 of 57 sites
- Collaborators: details revised at 1 of 1 entry
- Publications: details revised at 2 of 2 entries
- Minor Study sites revised (57)v216
- Minor Study completion date: Oct 3, 2025 to Oct 3, 2026v187
Show 9 earlier versionsHide 9 earlier versions
- Minor Study completion date: Sep 22, 2024 to Oct 3, 2025v184
- Minor Study sites revised (57)v183
- Notable Results first posted: Jul 16, 2024
- Secondary endpoints: details revised at 1 of 6 entries
- Minor Secondary endpoints: details revised at 1 of 6 entriesv180
- Minor Secondary endpoints revised (6)
- Primary endpoint revised
- Minor Secondary endpoints: details revised at 4 of 6 entriesv177
- Notable Start date: Oct 6, 2017 to Sep 9, 2018
- Study completion date: May 8, 2024 to Sep 22, 2024
- Minor Interventions: Bone Marrow Aspiration and Biopsy (Procedure), Computed Tomography (Procedure), Magnetic Resonance Imaging (Procedure), Trametinib (Drug) to Bone Marrow Aspiration and Biopsy (Procedure), Trametinib (Drug)
- Secondary endpoints: 2 to 6
- Study description shortened, about 13 words
- Minor Enrollment target: estimated 24 to confirmed 10
- Primary completion date changed from estimate of Mar 31, 2027 to Mar 31, 2023
- Study completion date: Mar 31, 2027 to May 8, 2024
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Objective Response
Timeframe: 12 cycles (1 cycle = 28 days)
Secondary (6)
Incidence of Adverse Events
Pharmacokinetic (PK) Parameters of Trametinib
Trametinib Concentrations
Mutant Allele Burden
Complete Response
Show 1 moreShow less
Duration of Response
Arms and interventions
Treatment (trametinib)Experimental
Patients receive trametinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a bone marrow aspiration or biopsy at baseline, on day 28 of cycles 1 and 2, at all subsequent odd numbered cycles, and at end of treatment.
Procedures: Bone Marrow Aspiration and Biopsy
Drugs: Trametinib
Sites
57 sites in 1 country